KP-1461

KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS.[1] It belongs to the class of nucleoside reverse transcriptase inhibitors.

KP-1461
Clinical data
Drug classReverse transcriptase inhibitor
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC16H23N4O6
Molar mass367.382 g·mol−1
3D model (JSmol)
SMILES
  • CCCCCCCOC(=O)NC1=NCN(C(=O)N1)[C@H]2C[C@@H]([C@H](O2)CO)O
InChI
  • InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1
  • Key:SZWIAFVYPPMZML-YNEHKIRRSA-N

KP-1461 is a prodrug of the active antiviral agent KP-1212.[2]

References
  1. "KP-1461". AIDSinfo. U.S. Department of Health and Human Services.
  2. "KP-1461". DrugBank. Canadian Institutes of Health Research.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.